POAI חוב כולל להון Predictive Oncology Corp

This chart of the total debt-to-equity price trend for Predictive Oncology (POAI) stands at 0.00. Predictive Oncology combines leading experts in oncology and AI to create breakthrough cancer therapy methods. However, a persistent lack of profitability during the implementation of predictive systems puts pressure on assets. The business relies on advanced tumor modeling and the strong scientific potential of management, which is striving to monetize its developments.

Predictive Oncology's high authority in AI-driven drug forecasting allows the company to attract resources on favorable terms, as reflected in the debt-to-equity ratio history on GURU.Markets. This ratio compares total liabilities to net assets, measuring the business's dependence on external borrowings and confirming either financial stability or the risk of excessive leverage.